Homeostasis of Glucose and Lipid in Non-Alcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Industrialized society-caused dysregular human behaviors and activities such as overworking, excessive dietary intake, and sleep deprivation lead to perturbations in the metabolism and the development of metabolic syndrome. Non-alcoholic fatty liver disease (NAFLD), the most common chronic liver disease worldwide, affects around 30% and 25% of people in Western and Asian countries, respectively, which leads to numerous medical costs annually. Insulin resistance is the major hallmark of NAFLD and is crucial in the pathogenesis and for the progression from NAFLD to non-alcoholic steatohepatitis (NASH). Excessive dietary intake of saturated fats and carbohydrate-enriched foods contributes to both insulin resistance and NAFLD. Once NAFLD is established, insulin resistance can promote the progression to the more severe state of liver endangerment like NASH. Here, we review current and potential studies for understanding the complexity between insulin-regulated glycolytic and lipogenic homeostasis and the underlying causes of NAFLD. We discuss how disruption of the insulin signal is associated with various metabolic disorders of glucoses and lipids that constitute both the metabolic syndrome and NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insulin signalling and the regulation of glucose and lipid metabolism
Saltiel, A. R., & Kahn, C. R. (2001) · Nature · doi:10.1038/414799a · Cited by 5,326 · cited 1×
“phosphatase for dephosphorylation and activation of glycogen synthase [38].”
BackgroundSteatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285 · cited 2×
“For the second hit, it can be a variety of factors, such as elevation of oxidative or endoplasmic reticulum (ER) stress, proinflammatory cytokines, mitochondrial dysfunction, and gut-derived bacterial endotoxin, which in turn leads to steatohepatitis and/or fibrosis [13,15].”
BackgroundDonnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 1×
“Enhanced de novo lipogenesis abnormally has been reported in patients with insulin resistance and contribute to a critical biochemical pathway for the pathogenesis of NAFLD [57].”
BackgroundGenetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
A circadian gene expression atlas in mammals: Implications for biology and medicine
Zhang, R., Lahens, N. F., Ballance, H. I., Hughes, M. E., & Hogenesch, J. B. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408886111 · Cited by 2,304 · cited 1×
“The bHLH-Periodic Acid Schiff transcriptional activators CLOCK and BMAL1 induce expression of negative feedback repressors Cryptochrome (Cry1 and Cry2) and Period (Per1, Per2, and Per3) to generate around 24-hr oscillations and affect up to 40% of the genomic transcripts [111].”
BackgroundSingh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077 · cited 1×
“Hence, elevation of triglyceride levels is considered to happen simultaneously with toxic metabolite formation, lipotoxicity, and liver injury and indicates that the system for turning food into energy is not working properly [53].”
BackgroundPhysiological significance of a peripheral tissue circadian clock
Lamia, K. A., Storch, K.-F., & Weitz, C. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806717105 · Cited by 1,048 · cited 1×
“For regulation of glucose homeostasis, loss of Bmal1 function in the liver caused excessive fluctuations in glycemia levels during the post-absorptive phase [115].”
BackgroundCopps, K. D., & White, M. F. (2012) · Diabetologia · doi:10.1007/s00125-012-2644-8 · Cited by 1,017 · cited 1×
“Most of the insulin-mediated metabolic actions are controlled by the PI3K–AKT/PKB pathway, which is phosphorylated by the insulin receptor through two major substrates, IRS-1 and IRS-2 [34].”
BackgroundMolecular physiology of the regulation of hepatic gluconeogenesis and glycolysis.
Pilkis, S. J., & Granner, D. K. (1992) · Annual Review of Physiology · doi:10.1146/annurev.ph.54.030192.004321 · Cited by 865 · cited 1×
“Therefore, insulin resistance induces an elevation of glycogenolysis and an increase in hepatic glycolytic intermediates, which leads to raised glycolysis and an inhibition of gluconeogenic flux to G6P by concurrent hyperglycemia [42].”
BackgroundBugianesi, E., Gastaldelli, A., Vanni, E., Gambino, R., Cassader, M., Baldi, S., Ponti, V., Pagano, G., Ferrannini, E., & Rizzetto, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1682-x · Cited by 770
Liver X receptors in lipid signalling and membrane homeostasis
Wang, B., & Tontonoz, P. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0037-x · Cited by 722 · cited 3×
“Therefore, new potent and effective LXR agonists without the side effects have been developed for clinical usage including a synthetic oxysterol N,N-dimethyl-3β- hydroxycholenamide (DMHCA), CS-8080, BMS-779788, and LXR-623 [92].”
BackgroundLiang, G., Yang, J., Horton, J. D., Hammer, R. E., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111421200 · Cited by 669 · cited 2×
“However, Srebp-1c−/− mice with T0901317 treatment, a LXRs agonist, still express a subset of lipogenic genes and a modest increase in fatty acid synthesis that indicate another mechanism mediated by LXRs can partially activate hepatic lipogenesis [82,94].”
BackgroundTranscriptional regulation of hepatic lipogenesis
Wang, Y., Viscarra, J., Kim, S.-J., & Sul, H. S. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4074 · Cited by 646
Gastaldelli, A., Cusi, K., Pettiti, M., Hardies, J., Miyazaki, Y., Berria, R., Buzzigoli, E., Sironi, A. M., Cersosimo, E., Ferrannini, E., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.068 · Cited by 629 · cited 1×
“As the production rates of glucose are high aberrantly in hepatocyte in the presence of high insulin level, it is characterized as a sign of hepatic insulin resistance [27].”
BackgroundCrosstalk between components of circadian and metabolic cycles in mammals
Asher, G., & Schibler, U. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.01.006 · Cited by 601
Regulation of Sterol Synthesis in Eukaryotes
Espenshade, P. J., & Hughes, A. L. (2007) · Annual Review of Genetics · doi:10.1146/annurev.genet.41.110306.130315 · Cited by 593
Cryptochrome mediates circadian regulation of cAMP signaling and hepatic gluconeogenesis
Zhang, E. E., Liu, Y., Dentin, R., Pongsawakul, P. Y., Liu, A. C., Hirota, T., Nusinow, D. A., Sun, X., Landais, S., Kodama, Y., et al. (2010) · Nature Medicine · doi:10.1038/nm.2214 · Cited by 567 · cited 1×
“In addition, Cry1 regulates hepatic gluconeogenesis through binding to G protein-coupled receptors and attenuates the transactivation of gluconeogenic genes [117].”
BackgroundDongiovanni, P., Petta, S., Maglio, C., Fracanzani, A. L., Pipitone, R., Mozzi, E., Motta, B. M., Kaminska, D., Rametta, R., Grimaudo, S., et al. (2015) · Hepatology · doi:10.1002/hep.27490 · Cited by 533 · cited 1×
“Similarly, the variant rs58542926 E167K in transmembrane 6 superfamily member 2 (TM6SF2) gene which is involved in VLDL secretion, has been associated with the pathogenesis of NAFLD and with liver disease severity [63].”
BackgroundSayiner, M., Koenig, A., Henry, L., & Younossi, Z. M. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.001 · Cited by 529
Thoma, C., Day, C. P., & Trenell, M. I. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.06.010 · Cited by 523 · cited 1×
“Overeating, consumption of energy dense, nutritionally imbalanced and appetite dysregulating food have been reported to be associated with NAFLD, and lifestyle modification usually can improve hepatic steatosis and liver fibrosis [10].”
BackgroundCircadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis
Kettner, N. M., Voicu, H., Finegold, M. J., Coarfa, C., Sreekumar, A., Putluri, N., Katchy, C. A., Lee, C., Moore, D. D., & Fu, L. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.007 · Cited by 508
Schwarz, J.-M., Linfoot, P., Dare, D., & Aghajanian, K. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.1.43 · Cited by 496
PER2 controls lipid metabolism by direct regulation of PPARγ
Grimaldi, B., Bellet, M. M., Katada, S., Astarita, G., Hirayama, J., Amin, R. H., Granneman, J. G., Piomelli, D., Leff, T., & Sassone-Corsi, P. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.10.005 · Cited by 489
Biddinger, S. B., Hernandez-Ono, A., Rask-Madsen, C., Haas, J. T., Alemán, J. O., Suzuki, R., Scapa, E. F., Agarwal, C., Carey, M. C., Stephanopoulos, G., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.11.013 · Cited by 469
Circadian Disruption Leads to Insulin Resistance and Obesity
Shi, S.-Q., Ansari, T. S., McGuinness, O. P., Wasserman, D. H., & Johnson, C. H. (2013) · Current Biology · doi:10.1016/j.cub.2013.01.048 · Cited by 452
Glucocorticoid regulation of the circadian clock modulates glucose homeostasis
So, A. Y.-L., Bernal, T. U., Pillsbury, M. L., Yamamoto, K. R., & Feldman, B. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909733106 · Cited by 431 · cited 1×
“Moreover, induction of Per2 by glucocorticoids was demonstrated to affect glucose metabolism in mice with hyperglycemic conditions which are protected from glucose intolerance as lose of glucocorticoid response element in the Per2 promoter [118].”
BackgroundPuri, P., Daita, K., Joyce, A., Mirshahi, F., Santhekadur, P. K., Cazanave, S., Luketic, V. A., Siddiqui, M. S., Boyett, S., Min, H., et al. (2018) · Hepatology · doi:10.1002/hep.29359 · Cited by 426 · cited 10×
“Obeticholic acid (OCA), a selective FXR agonist, is the first synthetic bile acid for the treatment of NASH that showed the potential anti-inflammatory and anti-fibrotic effects in the liver [129].”
BackgroundInfluentialMeta-analysis on shift work and risks of specific obesity types
Sun, M., Feng, W., Wang, F., Li, P., Li, Z., Li, M., Tse, G., Vlaanderen, J., Vermeulen, R., & Tse, L. A. (2018) · Obesity Reviews · doi:10.1111/obr.12621 · Cited by 391
Jiang, Z. Y., Zhou, Q. L., Coleman, K. A., Chouinard, M., Boese, Q., & Czech, M. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1332633100 · Cited by 378
Roles of diacylglycerols and ceramides in hepatic insulin resistance
Petersen, M. C., & Shulman, G. I. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.04.004 · Cited by 373
Snorgaard, O., Poulsen, G. M., Andersen, H. K., & Astrup, A. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000354 · Cited by 351
Disrupting Circadian Homeostasis of Sympathetic Signaling Promotes Tumor Development in Mice
Lee, S., Donehower, L. A., Herron, A. J., Moore, D. D., & Fu, L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010995 · Cited by 286
Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids
Vatner, D. F., Majumdar, S. K., Kumashiro, N., Petersen, M. C., Rahimi, Y., Gattu, A. K., Bears, M., Camporez, J.-P. G., Cline, G. W., Jurczak, M. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423952112 · Cited by 235 · cited 1×
“Importantly, the substrate provided from insulin-resistant adipocyte contributes the additional triglyceride synthesis in the liver [31].”
BackgroundSweet Sixteenth for ChREBP: Established Roles and Future Goals
Abdul-Wahed, A., Guilmeau, S., & Postic, C. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.004 · Cited by 231
Jones, D., Boudes, P. F., Swain, M. G., Bowlus, C. L., Galambos, M. R., Bacon, B. R., Doerffel, Y., Gitlin, N., Gordon, S. C., Odin, J. A., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30246-7 · Cited by 191
Cited by
Wang, R., Li, B., Lam, S. M., & Shui, G. (2020) · Journal of Genetics and Genomics · doi:10.1016/j.jgg.2019.11.009 · Cited by 330
Harrison, S. A., Ratziu, V., Boursier, J., Francque, S., Bedossa, P., Majd, Z., Cordonnier, G., Sudrik, F. B., Darteil, R., Liebe, R., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30252-1 · Cited by 255
NAFLD and HBV interplay - related mechanisms underlying liver disease progression
Tourkochristou, E., Assimakopoulos, S. F., Thomopoulos, K., Marangos, M., & Triantos, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.965548 · Cited by 70
“Thus, HBV infection could have an effect on NAFLD development by promoting significant metabolic changes, associated with NAFLD (97).”
BackgroundYong, Z., Ruiqi, W., Hongji, Y., Ning, M., Chenzuo, J., Yu, Z., Zhixuan, X., Qiang, L., Qibing, L., Weiying, L., et al. (2021) · Journal of Immunology Research · doi:10.1155/2021/4084566 · Cited by 48
“AMPK agonists, such as metformin, berberine, and gastrodin, were considered potential drugs used for the treatment of a variety of diseases related to glucose and lipid metabolism disorders, including NAFLD, diabetes, and cardiovascular and cerebrovascular diseases [13, 31].”
BackgroundZafer, M., Tavaglione, F., Romero‐Gómez, M., & Loomba, R. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70196 · Cited by 47
Metadata
- Authors
- Chao, H.-W., Chao, S.-W., Lin, H., Ku, H.-C., & Cheng, C.-F.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-01-13
- Volume
- 20
- Issue
- 2
- Pages
- 298
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2909835632
- Cited by
- 180
- References
- 37
- FWCI
- 12.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.